Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
Sarcomas gather a heterogeneous group of mesenchymal malignant tumors including more than 150 different subtypes. Most of them represent aggressive tumors with poor prognosis at the advanced stage, despite the better molecular characterization of these tumors and the development of molecular-driven...
Main Authors: | Mina Fazel, Armelle Dufresne, Hélène Vanacker, Waisse Waissi, Jean-Yves Blay, Mehdi Brahmi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/6/1643 |
Similar Items
-
Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?
by: Siddh van Oost, et al.
Published: (2021-08-01) -
Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?
by: Andrej Ozaniak, et al.
Published: (2021-08-01) -
Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond
by: Axel de Bernardi, et al.
Published: (2022-02-01) -
Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
by: Janina Świderska, et al.
Published: (2021-12-01) -
Exploring the landscape of immunotherapy approaches in sarcomas
by: Pampina Pilavaki, et al.
Published: (2023-01-01)